# Michael Dempsey

> Michael Dempsey is a seed investor at Compound (New York) backing Software and Biotechnology. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Compound](https://shizune.co/investors/profile/metamorphic-ventures-llc)
- Location: New York, United States
- Total investments: 8
- Last investment: Jan 2025
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/michaelhdempsey
- X (Twitter): http://twitter.com/mhdempsey
- Website: http://michaeldempsey.me

Michael Dempsey is a seed investor at Compound in New York focused on Software and Biotechnology. Michael Dempsey is the General Partner at Compound.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 3 | 38% |
| Biotechnology | 2 | 25% |
| Machine Learning | 2 | 25% |
| Artificial Intelligence | 2 | 25% |
| Apps | 1 | 13% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 38% |
| Pre-Seed | 2 | 25% |
| Series A | 1 | 13% |
| Series B | 1 | 13% |
| Funding Round | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NOAT | We create tools that kill smoking. | $7M | Seed | Jan 01, 2025 |  |
| Plural Energy | Plural Energy helps investors invest directly in renewable energy projects. The company utilizes blockchain-enabled smart contracts to provide constant yield and liquidity to investors. | $2.3M | Pre-Seed | May 30, 2024 |  |
| Bionaut Labs | Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality. By creating a new medical modality of remote-controlled micro-robots called Bionauts, the company can transform the way the biopharmaceutical industry develops treatments, allowing them to engineer the therapeutic index forefficacy and maintain safety.Bionaut Labs is focused on helping patients suffering from debilitating brain diseases who have few available treatment options. The anatomical targeting capabilities of the Bionaut platform make new therapeutics technologies such as gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings. | $43.2M | Series B | Nov 28, 2022 |  |
| Runway | Runway provides a suite of generative artificial intelligence tools that enable the creation and editing of images, videos, animations, and multimedia content using text prompts or visual inputs. The company offers models and creative tooling that support video generation from text or other media, image synthesis, and motion-aware editing within abrowser-based platform, along with APIs for integrating capabilities into external workflows. Runway’s technology includes iterative model versions such as Gen-4 and Aleph that help users direct visual style, scene continuity, and character consistency in generated sequences. Its platform also includes features for masking, compositing, motion tracking, and additional creative controls that work alongside generation models to support production workflows. Runway is positioned as an AI-driven creative toolkit for storytellers, filmmakers, and content producers seeking to prototype and produce visual content with machine learning assistance. | $8.5M | Series A | Dec 16, 2020 |  |
| Bionaut Labs | Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality. By creating a new medical modality of remote-controlled micro-robots called Bionauts, the company can transform the way the biopharmaceutical industry develops treatments, allowing them to engineer the therapeutic index forefficacy and maintain safety.Bionaut Labs is focused on helping patients suffering from debilitating brain diseases who have few available treatment options. The anatomical targeting capabilities of the Bionaut platform make new therapeutics technologies such as gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings. |  | Seed | Jul 02, 2019 |  |
| Alectio | The Alectio platform is the first full-stack, end-to-end, ML-driven self-serve DataPrepOps platform® enabling ML teams to prepare, curate, annotate, manage, version and visualize their training data in a few clicks, in near-real-time and quasi-automated manner.Alectio's proprietary technology is based on the fundamental belief that ML modelscan be trained with the same (sometimes better) performance with just a fraction of the data (which means lower labeling, storage and compute costs, and eventually the possibility of training on the edge). Data Scientists wrap their regular model and raw data with the Alectio's SDK and the Alectio curation engine guides the training process strategically so that the model gets trained on the most informative data; they'll never have to spend a minute on data preparation again!We're neither a labeling company nor an MLOps company: we're building a new category providing the entire workflow to prepare data during training which allows ML experts to build models and datasets simultaneously, reducing time to market, and a new training paradigm that will lead orgs to actual AI profitability.Alectio uncovers the smart data inside your big data, unlocking model performance and saving machine learning experts both time and money. | $600K | Pre-Seed | Jun 01, 2019 |  |
| Culture Biosciences | Culture Biosciences provides a platform of cloud-connected bioreactors, software tools, and process development services that support upstream bioprocess development for biotech and biopharma applications. The company’s offerings include remote experiment design, monitoring, and data analysis through an integrated cloud software interface pairedwith single-use bioreactors for microbial fermentation and cell culture experimentation. Its services encompass clone and strain screening, process optimization, characterization, and bioprocess modeling to help scientific teams refine and scale their workflows. Clients access real-time data and analytics to inform decisions and collaborate across teams using the platform’s tools. Culture Biosciences’s technology is used to advance development of therapeutics, synthetic biology products, and related bioprocesses. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California. | $5.5M |  | Feb 12, 2019 |  |
| Runway | Runway provides a suite of generative artificial intelligence tools that enable the creation and editing of images, videos, animations, and multimedia content using text prompts or visual inputs. The company offers models and creative tooling that support video generation from text or other media, image synthesis, and motion-aware editing within abrowser-based platform, along with APIs for integrating capabilities into external workflows. Runway’s technology includes iterative model versions such as Gen-4 and Aleph that help users direct visual style, scene continuity, and character consistency in generated sequences. Its platform also includes features for masking, compositing, motion tracking, and additional creative controls that work alongside generation models to support production workflows. Runway is positioned as an AI-driven creative toolkit for storytellers, filmmakers, and content producers seeking to prototype and produce visual content with machine learning assistance. | $2M | Seed | Dec 01, 2018 |  |

8 of 8 investments shown.

## Co-investors
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 3 deals together
- [Lux Capital](https://shizune.co/investors/profile/lux-capital) — VC Fund, 3 deals together
- [Upfront Ventures](https://shizune.co/investors/profile/upfront-ventures) — VC Fund, 3 deals together
- [Amplify Partners](https://shizune.co/investors/profile/amplify-partners) — VC Fund, 2 deals together
- [Revolution](https://shizune.co/investors/profile/revolution) — VC Fund, 2 deals together
- [Bold Capital Partners](https://shizune.co/investors/profile/bold-capital) — VC Fund, 1 deal together

## About Compound

VC Fund · New York, United States

Compound is a venture capital firm that invests in bleeding-edge technology built by outliers. They have partnered with elite operators that understand the intricacies of many different industries and various components of businesses, that help them navigate the complex systems in which each startup lives by removing roadblocks and compoundinggrowth.Compound is based in New York City.

5 contacts available at Compound.

| Name | Title | Profile |
| --- | --- | --- |
| Dan Zigmond | Board Partner | https://shizune.co/investors/profile/dan-zigmond |
| David Hirsch | Managing Partner | https://shizune.co/investors/profile/david-hirsch |
| Josh Nussbaum | EIR | https://shizune.co/investors/profile/josh-nussbaum |
| Maddy Mestman | Contracted | https://shizune.co/investors/profile/maddy-mestman |
| Michael Dempsey | General Partner; Partner | https://shizune.co/investors/profile/michael-dempsey |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Michael Dempsey invest in?

Michael Dempsey invests primarily in Software, Biotechnology and Machine Learning startups, most often at Seed and Pre-Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Michael Dempsey last invest?

The most recent investment recorded for Michael Dempsey closed in Jan 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co